A phase I study evaluating the safety and tolerability of PS-341(bortezomib)and carboplatin in patients with platinum- and taxane-resistant recurrent ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.

Trial Profile

A phase I study evaluating the safety and tolerability of PS-341(bortezomib)and carboplatin in patients with platinum- and taxane-resistant recurrent ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Bortezomib; Carboplatin
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2009 Actual patient number (21) added as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.
    • 24 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top